



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87757

Toshiyuki TAKASU, et al.

Appln. No.: 10/534,290

Group Art Unit: 3736

Confirmation No.: 9818

Examiner: Not yet assigned

Filed: May 09, 2005

For: REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE
DERIVATIVE AS THE ACTIVE INGREDIENT

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/534,290

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Mark Boland
Registration No: 32,197

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 13, 2006

Substitute for Form 1449 A & B/PTO		INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
				Application Number	10/534,290
		Confirmation Number	9818		
		Filing Date	May 09, 2005		
		First Named Inventor	Toshiyuki TAKASU		
		Art Unit	3736		
		Examiner Name	Not yet assigned		
Sheet 1 of		Attorney Docket Number	Q87757		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,069,176	A	05/30/2000	Tsuchiya et al.
		US			
		US			
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Penelope A. Longhurst et al., "Pharmacological characterization of β -adrenoceptors mediating relaxation of the rat urinary bladder in vitro" (1999), British Journal of Pharmacology, Vol. 127, pp. 1744-1750	
		Yasuhiko Igawa et al., "RELAXANT EFFECTS OF ISOPROTERENOL AND SELECTIVE β -3ADREENOCEPTOR AGONISTS ON NORMAL LOW COMPLIANT AND HYPERREFLEXIC HUMAN BLADDERS" (2001), The Journal of Urology, Vol. 165, pp. 240-244	
		Paul Abrams et al., "The Standardisation of Terminology of Lower Urinary Tract Functions: Report from the Standardisation Sub-committee of the International Continence Society" (2002), Neurourology and Urodynamics, 21: pp. 167-178	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.